January 7, 2013
When looking at the obesity drug space, investors tend to focus on VIVUS' (NASDAQ: VVUS ) Qsymia and Arena Pharmaceuticals' (NASDAQ: ARNA ) Belviq.
But have they already forgotten about the third potential player: Orexigen Therapeutics (NASDAQ: OREX ) ?
Orexigen's success hinges on approval from the Food and Drug Administration on its weight-loss drug Contrave, and the company released news today that suggests it is inching its way closer to a final decision. In the following video, health care analyst Max Macaluso breaks down the news, explains why shares of Orexigen were static today, and also notes one major risk that investors can't ignore with this stock.
What's inside Supernova?
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.